Loading clinical trials...
Loading clinical trials...
A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis
Conditions
Interventions
ALKS 8700
Locations
115
United States
Alkermes Investigational Site
Cullman, Alabama, United States
Alkermes Investigational Site
Phoenix, Arizona, United States
Alkermes Investigational Site
Phoenix, Arizona, United States
Alkermes Investigational Site
Phoenix, Arizona, United States
Alkermes Investigational Site
Tucson, Arizona, United States
Alkermes Investigational Site
Berkeley, California, United States
Start Date
December 10, 2015
Primary Completion Date
June 1, 2021
Completion Date
November 11, 2021
Last Updated
July 26, 2022
NCT07325292
NCT05748015
NCT06433765
NCT04876339
NCT07466823
NCT05344469
Lead Sponsor
Biogen
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions